厄洛替尼治疗晚期非小细胞肺癌的临床疗效及安全性观察

Observation on clinical efficacy and safety of erlotinib in the treatment of advanced non-small cell lung cancer

目的 探讨厄洛替尼治疗晚期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法 回顾性纳入中国科学技术大学附属第一医院(安徽省立医院)收治的69例晚期非小细胞肺癌患者病历资料,根据NSCLC患者确诊后应用药物治疗种类的不同,将69例纳入患者分为对照组和观察组。观察组(34例)给予厄洛替尼治疗,对照组(35例)给予常规化疗,比较2组的临床疗效及不良反应的差异。结果 2组的客观缓解率及疾病控制率比较,差异均无统计学意义(P>0.05);对照组和观察组的中位无进展生存期分别为4.2个月和12.6个月,差异有统计学意义(P<0.05)。观察组患者的性别、年龄、治疗时机和表皮生长因子受体突变类型对中位无进展生存期均无显著影响(P>0.05)。观察组不良事件以皮疹和转氨酶升高为主,其中皮疹的发生率高于对照组(P<0.05)。结论 相对常规化疗,厄洛替尼有利于疾病的控制、显著延长生存时间,但其皮疹的毒性反应更大。

Objective To probe into the clinical efficacy and safety of erlotinib in patients with advanced non-small cell lung cancer.Methods Sixty-nine patients with advanced NSCLC in the the First Affiliated Hospital of USTC were retrospectively enrolled.Patients were divided into two groups,the observation group(n=34)received erlotinib treatment,and the control group(n=35)received conventional chemotherapy,and the differences in clinical efficacy and adverse effects between the two groups were compared.Results The difference of objective remission and disease control rates between the two groups were not statistically significant(P>0.05).The median Progression-free survival of the control group and observation group was 4.2 months and 12.6 months,respectively,with ststistical significant differences in survival(P<0.05).Gender,age,treatment timing and type of EGFR mutation had no effect on median progression-free survival in the observation group(P>0.05).The adverse events in observation group were mainly rash and transaminase increase,and the incidence of rash was higher than that in control group(P<0.05).Conclusions Compared with conventional chemotherapy,erlotinib is benefical to the control of the disease and significantly prolonged survival time,but the toxic reaction of the rash was more severe.